Testing telitacicept for systemic sclerosis safety and effectiveness
Treatments studied
Part of Skin clinical trials.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of systemic sclerosis (scleroderma).
- You need to have active disease, like new skin thickening or worsening in two new body areas, even after 6 months of standard therapy.
- Your lung function must be at least 50% of normal (measured by a test called FVC).
- You must test positive for certain antibodies (ANA or scleroderma-related).
- You cannot be pregnant, planning a pregnancy in the next year, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This Phase 2 study tests itacitinib, a targeted medicine, to see if it can safely improve diffuse systemic sclerosis (a hardening/tightening of the skin and organ involvement). You may be eligible if you have active disease or it has been present less than 3 years.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This study tests a new type of cell therapy (CAR T-cells) to see if it works better than current treatments for active systemic sclerosis. It is designed for people whose lung disease is not well controlled by standard therapy.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.